Gyre Therapeutics, a biotechnology firm focusing on chronic organ diseases, announced today that the National Medical Products Administration of China has approved Gyre Pharmaceuticals’ avatrombopag maleate tablets. These tablets are for treating thrombocytopenia (“TP”) linked to chronic liver disease (“CLD”) in adults undergoing elective diagnostic procedures or therapy. TP is a common hematologic issue in CLD patients and can be severe in advanced cases.

Gyre Therapeutics, stated, “The NMPA's approval of avatrombopag maleate tablets is a significant milestone for Gyre as we expand our portfolio of rare disease treatments and advance therapies for CLD patients. We are committed to launching avatrombopag in China to meet the urgent needs of patients affected by this condition.”

Gyre Pharmaceuticals acquired avatrombopag through an agreement with Nanjing Healthnice Pharmaceutical Technology Co., Ltd. in June 2021. Avatrombopag, an oral thrombopoietin receptor agonist (“TPO-RA”), was initially approved by the U.S. Food and Drug Administration (“FDA”) in May 2018 for treating TP in adults with CLD, with subsequent approval in June 2019 for immune thrombocytopenia.

 

Source: globenewswire.com

Report Abuse